{"transactions":[{"id":2742030,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"exercise","acquired":false,"shares":3726963,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held of record by DCVC V, L.P. (\"DCVC V\"). DCVC V GP, LLC (\"DCVC V GP\") is the general partner of DCVC V and has sole voting and dispositive power with regard to the shares held by DCVC V. Matthew Ocko and Zachary Bogue are the managing members of DCVC V GP and share voting and dispositive power with respect to the shares held by DCVC V. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3726963},"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742029,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"exercise","acquired":false,"shares":730353,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held of record by DCVC Opportunity Fund II, L.P. (\"DCVC Opp Fund II\"). DCVC Opportunity Fund II GP, LLC (\"DCVC Opp Fund II GP\") is the general partner of DCVC Opp Fund II and has sole voting and dispositive power with regard to the shares held by DCVC Opp Fund II. Matthew Ocko and Zachary Bogue are the managing members of DCVC Opp Fund II GP and share voting and dispositive power with respect to the shares held by DCVC Opp Fund II. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":730353},"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742028,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"exercise","acquired":false,"shares":1095529,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the shares held by DCVC IV. Matthew Ocko and Zachary Bogue are the managing members of DCVC IV GP and share voting and dispositive power with respect to the shares held by DCVC IV. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1095529},"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742027,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"exercise","acquired":false,"shares":3220788,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held of record by DCVC Opportunity Fund II, L.P. (\"DCVC Opp Fund II\"). DCVC Opportunity Fund II GP, LLC (\"DCVC Opp Fund II GP\") is the general partner of DCVC Opp Fund II and has sole voting and dispositive power with regard to the shares held by DCVC Opp Fund II. Matthew Ocko and Zachary Bogue are the managing members of DCVC Opp Fund II GP and share voting and dispositive power with respect to the shares held by DCVC Opp Fund II. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3220788},"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742026,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"exercise","acquired":false,"shares":1073595,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the shares held by DCVC IV. Matthew Ocko and Zachary Bogue are the managing members of DCVC IV GP and share voting and dispositive power with respect to the shares held by DCVC IV. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1073595},"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742025,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"exercise","acquired":false,"shares":3771996,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the shares held by DCVC IV. Matthew Ocko and Zachary Bogue are the managing members of DCVC IV GP and share voting and dispositive power with respect to the shares held by DCVC IV. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3771996},"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742024,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"other","acquired":true,"shares":3726963,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held of record by DCVC V, L.P. (\"DCVC V\"). DCVC V GP, LLC (\"DCVC V GP\") is the general partner of DCVC V and has sole voting and dispositive power with regard to the shares held by DCVC V. Matthew Ocko and Zachary Bogue are the managing members of DCVC V GP and share voting and dispositive power with respect to the shares held by DCVC V. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":3726963,"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742023,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"other","acquired":false,"shares":3726963,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held of record by DCVC V, L.P. (\"DCVC V\"). DCVC V GP, LLC (\"DCVC V GP\") is the general partner of DCVC V and has sole voting and dispositive power with regard to the shares held by DCVC V. Matthew Ocko and Zachary Bogue are the managing members of DCVC V GP and share voting and dispositive power with respect to the shares held by DCVC V. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742022,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"exercise","acquired":true,"shares":3726963,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held of record by DCVC V, L.P. (\"DCVC V\"). DCVC V GP, LLC (\"DCVC V GP\") is the general partner of DCVC V and has sole voting and dispositive power with regard to the shares held by DCVC V. Matthew Ocko and Zachary Bogue are the managing members of DCVC V GP and share voting and dispositive power with respect to the shares held by DCVC V. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":3726963,"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742021,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"other","acquired":true,"shares":3951141,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held of record by DCVC Opportunity Fund II, L.P. (\"DCVC Opp Fund II\"). DCVC Opportunity Fund II GP, LLC (\"DCVC Opp Fund II GP\") is the general partner of DCVC Opp Fund II and has sole voting and dispositive power with regard to the shares held by DCVC Opp Fund II. Matthew Ocko and Zachary Bogue are the managing members of DCVC Opp Fund II GP and share voting and dispositive power with respect to the shares held by DCVC Opp Fund II. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":3951141,"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742020,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"other","acquired":false,"shares":3951141,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held of record by DCVC Opportunity Fund II, L.P. (\"DCVC Opp Fund II\"). DCVC Opportunity Fund II GP, LLC (\"DCVC Opp Fund II GP\") is the general partner of DCVC Opp Fund II and has sole voting and dispositive power with regard to the shares held by DCVC Opp Fund II. Matthew Ocko and Zachary Bogue are the managing members of DCVC Opp Fund II GP and share voting and dispositive power with respect to the shares held by DCVC Opp Fund II. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742019,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"exercise","acquired":true,"shares":3951141,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held of record by DCVC Opportunity Fund II, L.P. (\"DCVC Opp Fund II\"). DCVC Opportunity Fund II GP, LLC (\"DCVC Opp Fund II GP\") is the general partner of DCVC Opp Fund II and has sole voting and dispositive power with regard to the shares held by DCVC Opp Fund II. Matthew Ocko and Zachary Bogue are the managing members of DCVC Opp Fund II GP and share voting and dispositive power with respect to the shares held by DCVC Opp Fund II. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":3951141,"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742018,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"other","acquired":true,"shares":5941120,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the shares held by DCVC IV. Matthew Ocko and Zachary Bogue are the managing members of DCVC IV GP and share voting and dispositive power with respect to the shares held by DCVC IV. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":5941120,"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742017,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"other","acquired":false,"shares":5941120,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the shares held by DCVC IV. Matthew Ocko and Zachary Bogue are the managing members of DCVC IV GP and share voting and dispositive power with respect to the shares held by DCVC IV. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742016,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"exercise","acquired":true,"shares":5941120,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the shares held by DCVC IV. Matthew Ocko and Zachary Bogue are the managing members of DCVC IV GP and share voting and dispositive power with respect to the shares held by DCVC IV. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":5941120,"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}}]}